GTAC

Principal Investigator: Matt Harms, MD

Disease: ALS

Project Duration: 3 years

Primary Aim(s):

  • Aim 1: Identify and prospectively phenotype 1500 ALS/MND patients with paired DNA, RNA and iPSC-ready PBMC samples.
  • Aim 2: Generate, annotate, and analyze whole-genome and RNA sequencing for 1500 ALS/MND patients.
  • Aim 3: Integrate whole-genome sequence data with RNA-seq derived transcriptome data and clinical phenotypes for 1500 ALS/MND patients. 

How CIB accelerates this project:

CIB operates as the data coordination core.
Platforms used: NeuroBANK™, NeuroGUID